Abstract
The standard of care for HCV genotype 1 (the most common HCV genotype) is a protease inhibitor combined with PEG-IFN and ribavirin for 24–48 weeks. “Although a sustained virologic response (SVR) is achieved in up to 75% of patients, tolerability of these regimens is poor, dosing is complex and development of resistance is common among patients who do not achieve SVR,” says Eric Lawitz. Now, two phase II trials from the USA have revealed that sofosbuvir—a uridine nucleotide analogue that selectively inhibits the HCV NS5B polymerase—is safe and effective in the treatment of patients with HCV infection.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
